オンコノバ・セラピューティクス【ONTX】の掲示板

>>69

２Qか３Qに3相試験開始の認可が下りたら何か動きがあるんじゃない？
供給はよー（ΦωΦ）

Progress on Oral Rigosertib Combination with Azacitidine for 1st-line HR-MDS
Following a productive end of Phase 2 meeting with the Food and Drug Administration (FDA) in the third quarter of 2016, a protocol for a pivotal Phase 3 trial is being developed. The Company expects to submit this protocol for review by regulatory agencies in the US and Europe in the second or third quarter of 2017.

ttp://investor.onconova.com/releasedetail.cfm?ReleaseID=1018795